The people sourcing,
screening, and stewarding capital.

M&A lawyer, entrepreneur, and investor. Board member of MassChallenge, founder and Board member of the Rhode Island–Israel Collaborative (RIIC), and on the Investment Committee of Purple Arch Ventures. MBA from Northwestern (Kellogg); LLB from the University of London.

Managing Director in Investment Banking at Stifel Financial. Co-founder of Mooreland Partners (acquired by Stifel, 2019). Joined Cherrystone in 2011, leading investments including Streamroot, Medumo, Narragansett Brewing, and Advanced Silicon Group. AB Amherst, MBA Harvard.

President of Grays Point Investments, a family office focused on private equity and real estate. Former Managing Director at Citigroup’s Corporate and Structured Finance businesses across the US, Japan, West Africa, Turkey, and the Middle East. BA Brown, MA Fletcher School.

Functional group leader for Economic & Valuation Services at KPMG’s Washington National Tax practice. Former economist at the Federal Reserve Bank of Boston and faculty at Johns Hopkins. PhD in Economics, UC Berkeley.

CFO at Flueid. 25+ years in venture capital, M&A, and corporate finance — advised on 50+ transactions in fintech, payments, and enterprise software. Co-founder of Beeline Loans. Georgetown finance, CFA.

Managing Partner and co-founder of Great River Capital Partners, a Boston PE firm acquiring mid-sized manufacturing and industrial-tech companies. Previously Partner at JMC Capital, Symmetric Capital, Ampersand. AB Bates, MBA Harvard.

Former Canadian Ambassador to China. Founded a leading boutique merchant bank in Beijing (acquired by Canaccord, 2011). Now with PacBridge Partners in Hong Kong. BA & MA McGill, additional graduate work at Toronto and Sciences Po Paris.

Former VP of Pharmaceutical Sciences Small Molecule at Pfizer (31-year career). Heads TGIR Consulting on leadership and innovation in life sciences. PhD Synthetic Organic Chemistry from Yale; BA Carleton. ACS Earl B. Barnes award.

Partner at PwC Deals Advisory. Advised on 150+ M&A transactions ranging from $10M to $10B+, with a focus on healthcare and life sciences. Providence College, MBA Columbia Business School.

Founding Partner of NEMIC (New England Medical Innovation Center) and Fellow of the Provost at RISD. Founding partner of Ximedica, one of the world’s leading medical-device developers; remains Chief Innovation Officer Emeritus.

Coordinates Cherrystone’s due diligence and final reports. Prior: Project Director at Micro Guard 47, Ops Manager at The Makery Brookline. BS Mechanical Engineering, Cornell; joint Master’s in Design Engineering, Brown & RISD.

35+ years in pharma and biotech. Co-founder of Akston Bioscience; former VP BD at SmartCells (sold to Merck for $500M+). Former Chief Business Officer at Elixir Pharmaceuticals; SVP at Cubist (acquired by Merck) and Nycomed Amersham (acquired by GE).